Precipio, Inc. (PRPO)
30.90
+1.10
(+3.69%)
USD |
NASDAQ |
Apr 30, 14:36
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 55.12M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 418.3% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 2.095 |
| Price to Book Value | 3.785 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.2509 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.69% |
Profile
| Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. It operates through the following business divisions: Pathology Services and Products. The Pathology Services division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. The Products divisions develops and commercializes proprietary assays designed for use by clinical laboratories. The company was founded on March 6, 1997 and is headquartered in New Haven, CT. |
| URL | http://www.precipiodx.com |
| Investor Relations URL | http://www.transgenomic.com/ir/investor-information/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 20, 2018 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. It operates through the following business divisions: Pathology Services and Products. The Pathology Services division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. The Products divisions develops and commercializes proprietary assays designed for use by clinical laboratories. The company was founded on March 6, 1997 and is headquartered in New Haven, CT. |
| URL | http://www.precipiodx.com |
| Investor Relations URL | http://www.transgenomic.com/ir/investor-information/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 20, 2018 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |